Table 1.
Experimental groups of mice by genotype and treatment regimen
| Mice | Treatment | Delivery route | Dose (mg/kg/day)† | Dose (mg/kg/per injection)† | Frequency | No. of mice (F+M)‡ |
|---|---|---|---|---|---|---|
|
| ||||||
| Prevention study | ||||||
|
| ||||||
| Abcc6 +/+ | ‒ | ‒ | ‒ | ‒ | ‒ | 6+6 |
| Abcc6−/− | ‒ | ‒ | ‒ | ‒ | ‒ | 5+6 |
| Abcc6−/− | INS-3001 | Osmotic pump | 0.16 | ‒ | Continuous | 5+5 |
| Abcc6−/− | INS-3001 | Osmotic pump | 0.8 | ‒ | Continuous | 4+6 |
| Abcc6−/− | INS-3001 | Osmotic pump | 4 | ‒ | Continuous | 3+3 |
| Abcc6−/− | INS-3001 | Osmotic pump | 20 | ‒ | Continuous | 5+4 |
| Abcc6−/− | INS-3001 | Osmotic pump | 100 | ‒ | Continuous | 3+4 |
| Abcc6−/− | INS-3001 | s.c. injection | 4 | 9 | Thrice weekly | 4+4 |
| Abcc6−/− | INS-3001 | s.c. injection | 14 | 100 | Once weekly | 5+5 |
| Abcc6−/− | INS-3001 | s.c. injection | 4 | 28 | Once weekly | 5+5 |
| Abcc6−/− | INS-3001 | s.c. injection | 0.8 | 5.6 | Once weekly | 5+5 |
| Established disease study | ||||||
| Abcc6−/− | ‒ | ‒ | ‒ | ‒ | ‒ | 5+4 |
| Abcc6−/− | INS-3001 | Osmotic pump | 4 | ‒ | Continuous | 0+6 |
†
INS-3001 was administered in sodium salt but the doses refer to the acid form of the compound.
‡
F, female; M, male; s.c., subcutaneous.